Comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy

Purpose To assess the optimal time of intravitreal conbercept (IVC) treatment prior to pars plana vitrectomy (PPV) in patients with severe proliferative diabetic retinopathy (PDR). Method This study was exploratory in nature. Forty-eight consecutive patients (48 eyes) with PDR were divided into four groups according to different IVC times (0.5 mg/0.05 mL) before PPV: group A (3 days), group B (7 days), group C (14 days), and group D (non-IVC). Intraoperative and postoperative effectiveness were assessed, and vitreous VEGF concentrations were detected. Result For intraoperative effectiveness, groups A and D had a higher incidence of intraoperative bleeding than groups B and C (P = 0.041). Furthermore, groups A-C required less surgical time than group D (P < 0.05). For postoperative effectiveness, group B had a significantly higher proportion of visual acuity that improved or remained unchanged than group D (P = 0.014), and groups A-C had lower proportions of postoperative bleeding than group D. The vitreous VEGF concentration of group B (67.04 ± 47.24 pg/mL) was significantly lower than that of group D (178.29 ± 110.50 pg/mL) (P = 0.005). Conclusion IVC treatment that was administered 7 days preoperatively was associated with better effectiveness and a lower vitreous VEGF concentration than its administration at other time points.

[1]  P. Xie,et al.  Monitoring intraocular proangiogenic and profibrotic cytokines within 7 days after adjunctive anti‐vascular endothelial growth factor therapy for proliferative diabetic retinopathy , 2021, Acta ophthalmologica.

[2]  P. Kaiser,et al.  Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study , 2021, British Journal of Ophthalmology.

[3]  S. Chaudhary,et al.  Proliferative diabetic retinopathy (PDR). , 2021, Disease-a-month : DM.

[4]  G. H. Chen,et al.  Intravitreal conbercept as an adjuvant in vitrectomy for proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials , 2021, Eye.

[5]  Xiaohong Gao,et al.  Effect of intravitreal conbercept injection on VEGF-A and -B levels in the aqueous and vitreous humor of patients with proliferative diabetic retinopathy , 2021, Experimental and therapeutic medicine.

[6]  You-xin Chen,et al.  Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis , 2020, Scientific Reports.

[7]  Jili Chen,et al.  Intravitreal Conbercept Injection as an Adjuvant in Vitrectomy with Silicone Oil Infusion for Severe Proliferative Diabetic Retinopathy. , 2020, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[8]  Junjie Ye,et al.  Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after intravitreal injection of conbercept as an adjunctive therapy for vitrectomy , 2020, Chinese medical journal.

[9]  C. Faselis,et al.  Microvascular complications of type 2 diabetes mellitus. , 2020, Current vascular pharmacology.

[10]  G. Abbott Detachment , 2018, Thucydides.

[11]  B. Zheng,et al.  Effect of intravitreal conbercept treatment before vitrectomy in proliferative diabetic retinopathy. , 2018, International journal of ophthalmology.

[12]  S. Charles,et al.  Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy , 2018, Journal of ophthalmology.

[13]  E. Alimanović-Halilović,et al.  Vitreous concentrations of vascular endothelial growth factor as a potential biomarker for postoperative complications following pars plana vitrectomy , 2018, Archives of medical science : AMS.

[14]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[15]  Sloan W. Rush,et al.  Preoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: A Randomized and Controlled Trial Comparing Interval Variation. , 2017, American journal of ophthalmology.

[16]  H. Dong,et al.  Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study , 2017, Eye.

[17]  Xiaoling Liu,et al.  EFFICACY AND SAFETY OF INTRAVITREAL CONBERCEPT INJECTIONS IN MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION , 2017, Retina.

[18]  M. Humayun,et al.  VISUAL AND ANATOMICAL OUTCOMES AFTER DIABETIC TRACTION AND TRACTION-RHEGMATOGENOUS RETINAL DETACHMENT REPAIR , 2017, Retina.

[19]  Liangzhang Tan,et al.  INTRAVITREAL CONBERCEPT (KH902) FOR SURGICAL TREATMENT OF SEVERE PROLIFERATIVE DIABETIC RETINOPATHY , 2016, Retina.

[20]  Ting Zhang,et al.  A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy , 2016, Journal of ophthalmology.

[21]  D. Maberley,et al.  ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis , 2015, Retina.

[22]  Peizeng Yang,et al.  Observation of total VEGF level in hyperglycemic mouse eyes after intravitreal injection of the novel anti-VEGF drug conbercept , 2015, Molecular vision.

[23]  K. Eng,et al.  A randomized study comparing the efficacy of bevacizumab and ranibizumab as pre-treatment for pars plana vitrectomy in proliferative diabetic retinopathy. , 2014, Ophthalmic surgery, lasers & imaging retina.

[24]  X. Chen,et al.  KH902 suppresses high glucose‐induced migration and sprouting of human retinal endothelial cells by blocking VEGF and PIGF , 2013, Diabetes, obesity & metabolism.

[25]  H. Goto,et al.  Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy. , 2012, Investigative ophthalmology & visual science.

[26]  Hong Li,et al.  Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit. , 2012, Experimental eye research.

[27]  T. Williamson,et al.  Surgical and visual outcome following 20-gauge vitrectomy in proliferative diabetic retinopathy over a 10-year period, evidence for change in practice , 2012, Eye.

[28]  J. Shaw,et al.  IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. , 2011, Diabetes research and clinical practice.

[29]  K. Park,et al.  The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. , 2011, Ophthalmology.

[30]  Y. Mizutani,et al.  DOSE OF INTRAVITREAL BEVACIZUMAB (AVASTIN) USED AS PREOPERATIVE ADJUNCT THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY , 2010, Retina.

[31]  Z. Kapran,et al.  TRANSCONJUNCTIVAL 25-GAUGE SUTURELESS VITRECTOMY AND SILICONE OIL INJECTION IN DIABETIC TRACTIONAL RETINAL DETACHMENT , 2008, Retina.

[32]  S Von Hagen,et al.  Epiretinal membrane removal in diabetic eyes: comparison of viscodissection with conventional methods of membrane peeling , 2003, The British journal of ophthalmology.

[33]  P. Rothwell,et al.  Meta-analysis of randomised controlled trials , 1997, The Lancet.

[34]  Dahua Xu,et al.  Pars plana vitrectomy assisted by intravitreal injection of conbercept enhances the therapeutic effect and quality of life in patients with severe proliferative diabetic retinopathy. , 2022, American journal of translational research.

[35]  A. de Laat,et al.  Network meta-analysis. , 2017, Journal of oral rehabilitation.